Covaxin has been developed on the WHO prequalified vero cell platform, which is globally recognised with a well-established track record of safety
Hyderabad: The encouraging results of phase-3 trials of Covaxin should reflect India’s emergence as the vaccine superpower, said Director General of Indian Council of Medical Research (ICMR), Dr. Balram Bhargava on Wednesday.
“The bench-to-bedside journey of a completely indigenous Covid-19 vaccine in less than eight months showcases the immense strength of Atmanirbhar Bharat (self-reliant India) to fight the odds and stand tall in the global public health community. It is also a testament to India’s emergence as a global vaccine superpower,” Dr. Bhargava said in a press release said.
Covaxin has been developed on the WHO prequalified vero cell platform, which is globally recognised with a well-established track record of safety. It also has the ability to neutralise the UK variant strain of SARS-CoV-2 virus.
Said Dr. Samiran Panda, Head, Epidemiology and Communicable Disease, ICMR and Director, National AIDS Research Institute, “The development and deployment of Covaxin ensures that India has a powerful weapon that will go a long way in helping us win the war against Covid-19.”
Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.